RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders

* wall-street.cz is not responsible for the content in this press release. 

US-patent

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing andcommercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has been granted a patent by the U.S. Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI‑109, for the treatment of fibrotic disorders. U.S. Patent Number 8,664,189, will expire in 2029. The Notice of Allowance was released on January 14, 2014 for this patent.

Continue reading ‘RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders’ »

RNAi tactic to fight disease offers new hope: Genzyme, Alnylam say they’re making progress

* wall-street.cz is not responsible for the content in this press release. 

rna-big-7228

From left: Phillip D. Zamore is codirector of the RNA Therapeutics Institute. Craig Mello and another scientist won a Nobel Prize for RNAi work. John Maraganore says Alnylam tailors RNAi for various targets.

Continue reading ‘RNAi tactic to fight disease offers new hope: Genzyme, Alnylam say they’re making progress’ »

Insider Trading activities of Galena Biopharma

 

Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2014-02 20,000 $98,740 487,500 $2,065,536 487,500 $731,137
2014-01 0 $0 2,321,765 $13,194,124 2,221,765 $2,765,771
2013-12 0 $0 0 $0 50,000 $36,000
2011-12 15,000 $9,590 0 $0 0 $0
2011-04 10,000 $9,500 0 $0 0 $0
2010-12 0 $0 3,093,881 $7,031,538 0 $0
2010-07 10,000 $22,290 5,000 $10,265 0 $0
2010-06 0 $0 2,000,000 $5,100,000 0 $0
2010-03 0 $0 719,081 $4,091,076 0 $0
2009-09 0 $0 500,000 $1,250,000 0 $0
2009-08 0 $0 8,990 $28,156 0 $0
2009-07 0 $0 2,893 $12,516 0 $0
2009-06 0 $0 50,685 $247,618 0 $0
2009-05 0 $0 29,407 $144,993 0 $0
2009-04 0 $0 45,809 $219,763 0 $0
2009-03 0 $0 56,657 $205,904 0 $0
2009-02 0 $0 6,500 $27,809 0 $0

Continue reading ‘Insider Trading activities of Galena Biopharma’ »